Investor Relations

News Release

Printer Friendly Version View printer-friendly version
<< Back
Five Clinical Presentations Highlight Shionogi Pharma, Inc.'s PSD502, an Investigational Treatment For Primary Premature Ejaculation

Data to be Presented at AUA 2010 Annual Meeting ATLANTA, GA, May 26, 2010 - Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., announced today that the investigational new drug PSD502, a topical metered dose spray which is being developed for the treatment of primary premature ejaculation (PE), will be the subject of five clinical presentations early next month. These data will be presented at the American Urological Association’s (AUA) 2010 Annual Meeting May 29 to June 3 in San Francisco.

The times, titles and lead authors of the data presentations follow. 


Presentation Title

Lead Author




June 01, 2010
8:40 – 8:50AM PT

An integrated summary of the results of two pivotal phase III studies of PSD502 for premature ejaculation (PE)

Ira D. Sharlip, MD, University of California at San Francisco, San Francisco, CA




June 01, 2010
8:50 – 9:00AM PT

Does time matter? Determination of the relationship between increasing ejaculatory latency in men with premature ejaculation and the domains of the index of premature ejaculation (IPE)

Stanley E. Althof, PhD, University of Miami Miller School of Medicine, West Palm Beach, FL




June 01, 2010
11:10 – 11:20AM PT

PSD502: A second phase III, randomized, double-blind, placebo-controlled study in premature ejaculation (PE) patients in the US and Europe

Culley C. Carson, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC




June 01, 2010
11:20 – 11:30AM PT

PSD502 appears to be effective in both circumcised and un-circumcised men with premature ejaculation (PE)

Wayne Hellstrom, MD, FACS, Tulane University School of Medicine, New Orleans, LA




June 01, 2010
1:50 – 2:00PM PT

Efficacy is maintained and may be enhanced using long-term (1yr) administration of PSD502 for premature ejaculation (PE)

Michael A. Perelman, PhD, New York Presbyterian Hospital, New York, NY


About Premature Ejaculation (PE)
For years, experts debated about the definition of premature ejaculation. In 2008, the International Society for Sexual Medicine presented an evidence-based definition of PE as agreed upon by a consensus of the world’s leading sexual health experts: a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.

About Shionogi & Co., Ltd.
Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi’s Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor and doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit For more information on Shionogi Pharma, Inc. based in Atlanta, Georgia, please visit

Contact: Shionogi Pharma, Inc.
Joseph T. Schepers
Telephone: +1-678-341-1401
Dave Schemelia
Telephone: +1-609-468-9325